January 9, 2024
1 minute read
Important points:
- Novartis will acquire Singapore-based Sunreno Therapeutics, which is developing treatments for IgA nephropathy.
- The sale includes exclusive rights to sell the drug in China and Singapore.
According to a press release, Novartis has agreed to acquire Sunreno Therapeutics, a clinical-stage company focused on developing treatments for kidney diseases.
Sunreno Therapeutics, founded in late 2021 as a joint venture between investors and Chinook Therapeutics, now part of Novartis, will develop two treatments targeting immunoglobulin A nephropathy, according to a release. The company holds exclusive rights in China and Singapore for its legal products, atrasentan and zigakibat.
Atrasentan is an oral endothelin A receptor antagonist in phase 3 trials. Digakivert (BION-1301) is a subcutaneously administered monoclonal antibody that targets proliferation-inducing ligands and is in Phase 3 trials, according to the release.
“Novartis’ acquisition of SanReno is a testament to the SanReno team’s unwavering dedication and constant innovation. It confirms our commitment to pushing the boundaries of kidney disease treatment.” Huang Haoyu Sanrino Therapeutics CEO said in a release. Huang added, “Today marks an exciting new chapter in our journey to make a meaningful impact in the field of kidney health.”